^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

AXL inhibition improves BRAF-targeted treatment in melanoma

Published date:
03/24/2022
Excerpt:
To evaluate the effect of the combination treatment in vivo, Melmet 1 xenografts were established and treated with AXLi, BRAFi or a combination of both, twice daily for 14 days (Fig. 6a)....Compared to either one of the mono-treatments, a significant regression in tumor size was observed when xenografts were treated with the AXLi and BRAFi combination.
DOI:
10.1038/s41598-022-09078-z